靶向成纤维细胞生长因子10/FGFR1在复发性类风湿关节炎中的作用与治疗潜力
研究结合单细胞RNA测序与空间转录组学,分析3例复发性与3例缓解期类风湿关节炎患者配对滑膜组织,发现复发性患者衬里层成纤维样滑膜细胞中FGF通路高度激活、FGF10表达增加;体外敲低FGF10可减少RANKL表达,重组FGF10增强骨侵蚀而FGFR1抑制剂减轻之,FGFR1抑制剂在胶原诱导性关节炎大鼠模型中显示治疗效应。
要点
- 复发性类风湿关节炎衬里层成纤维样滑膜细胞中FGF通路高度激活,FGF10表达增加经多重免疫组化证实。
- 体外敲低FGF10显著减少成纤维样滑膜细胞RANKL表达,重组FGF10增强原代人源血管翳细胞培养中的骨侵蚀。
- FGFR1抑制剂在胶原诱导性关节炎大鼠模型中显示治疗效应。
核心结论
- FGF通路是复发性类风湿关节炎的关键信号通路,靶向组织特异性抑制FGF10/FGFR1可能为治疗复发性类风湿关节炎患者提供新机会。
研究设计与样本
- 研究结合单细胞RNA测序与空间转录组学,对3例复发性类风湿关节炎和3例缓解期患者的6份配对滑膜组织样本进行测序。
- 采用定量实时PCR和多重免疫组化验证关键信号通路,并在体外及大鼠胶原诱导性关节炎模型中靶向关键信号。
主要发现
- 单细胞RNA测序鉴定出衬里层和亚衬里层成纤维样滑膜细胞亚群,差异分析显示复发性类风湿关节炎患者衬里层成纤维样滑膜细胞中FGF通路高度激活,多重免疫组化证实FGF10表达增加。
- 衬里层成纤维样滑膜细胞中I型干扰素通路亦激活,但体外刺激实验提示其独立于FGF10通路。
- 小干扰RNA敲低成纤维样滑膜细胞中FGF10显著降低核因子κB受体活化因子配体表达。
- 重组FGF10蛋白增强原代人源血管翳细胞培养中的骨侵蚀,而FGFR1抑制剂减轻该过程。
- 给予FGFR1抑制剂在胶原诱导性关节炎大鼠模型中显示治疗效应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Fibroblast-like synoviocytes (FLSs) contribute to inflammation and joint damage in rheumatoid arthritis (RA). However, the regulatory mechanisms of FLSs in relapse and remission of RA remain unknown. Identifying FLS heterogeneity and their underlying pathogenic roles may lead to discovering novel disease-modifying antirheumatic drugs. METHODS: Combining single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics, we sequenced six matched synovial tissue samples from three patients with relapse RA and three patients in remission. We analyzed the differences in the transcriptomes of the FLS subsets between the relapse and remitted phases. We validated several key signaling pathways using quantitative real-time PCR (qPCR) and multiplex immunohistochemistry (mIHC). We further targeted the critical signals in vitro and in vivo using the collagen-induced arthritis (CIA) model in rats. RESULTS: Lining and sublining FLS subsets were identified using scRNA-seq. Differential analyses indicated that the fibroblast growth factor (FGF) pathway was highly activated in the lining FLSs from patients with relapse RA for which mIHC confirmed the increased expression of FGF10. Although the type I interferon pathway was also activated in the lining FLSs, in vitro stimulation experiment suggested that it was independent of the FGF10 pathway. FGF10 knockdown by small interfering RNA in FLSs significantly reduced the expression of receptor activator of NF-κB ligand. Moreover, recombinant FGF10 protein enhanced bone erosion in the primary human-derived pannus cell culture, whereas the FGF receptor (FGFR) 1 inhibitor attenuated this process. Finally, administering an FGFR1 inhibitor displayed a therapeutic effect in a CIA rat model. CONCLUSION: The FGF pathway is a critical signaling pathway in relapse RA. Targeted tissue-specific inhibition of FGF10/FGFR1 may provide new opportunities to treat patients with relapse RA.
引用
- Meng X, Chen Z, Li T, et al. Role and Therapeutic Potential for Targeting Fibroblast Growth Factor 10/FGFR1 in Relapsed Rheumatoid Arthritis. Arthritis Rheumatol. 2023. PMID: 37584284. doi:10.1002/art.42674
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。